
Regulatory
Latest Content

FDA Approves Livsayis, Regeneron's First siRNA Therapy for Myasthenia Gravis

Novartis Trims Growth Target at Annual Management Day, Shares Slide

DISCO, AbbVie Sign AND-Gated Bispecific Deal Worth Up to $2.5B

How Agentic Models are Helping Physicians Provide Better Care

Johnson & Johnson's Strategic Shift: Why Diversification Is Giving Way to Focus

Shorts









Podcasts
Videos
All News

Dr. Joe Geraci of NetraMark explains how AI analysis of clinical trial data can uncover hidden responder subgroups, separate true drug responders from placebo responders, and potentially rescue drug assets that appeared to fail in Phase II.

Parexel’s Stacy Hurt explains why AI can speed up clinical research but can’t replace the lived experience of patients.

The month's biggest moves — from Pfizer and Blackstone's obesity co-funding agreement to Lilly's $3.5B Pennsylvania groundbreaking — answered in plain language.

White House withdraws Dr. Heidi Overton’s FDA commissioner nomination amid Senate GOP pushback, Pfizer and Verismo advance in vivo CAR-T manufacturing through new licensing deals, and Infinitus’s Ankit Jain discusses balancing workloads between humans and agentic AI.

The White House has withdrawn Dr. Heidi Overton’s nomination for FDA commissioner just a day before a Senate committee vote.

Verismo Therapeutics licenses in vivo CAR T engineering technology from Stanford Medicine, while Pfizer licenses in vivo CAR-T programs from Starna Therapeutics.

The future is agent-first but human when it matters — AI handles repetitive tasks while humans manage exceptions, complexity, and regulatory needs.

Gilead signs royalty-free licensing deals to broaden Ebola antiviral access, FDA approves Cosentyx for polymyalgia rheumatica and Wilserdly for ESR1-mutated breast cancer, and Infinitus’s Ankit Jain talks agentic AI’s role in pharma’s commercial model.

Gilead signs royalty-free licensing agreements with three generic manufacturers to expand future access to its investigational antiviral obeldesivir.

FDA submitted approvals for Novartis’s Cosentyx and Roche’s Wilserdly.

Agentic AI turns wasted windshield time into productive CRM updates and deploys always-on virtual reps to support providers whenever information is needed.

FDA approves three new therapies, a wave of dealmaking led by Johnson & Johnson, Eli Lilly, AmyriAD Therapeutics, and Sanofi, and Ossium Health’s Kevin Caldwell joins The Ron Lanton Report on rebuilding bone marrow transplants around deceased-donor marrow.

New deals this week span across ophthalmology to Alzheimer’s, with three new acquisitions and one research collaboration.

FDA approves Genentech’s Gazyva, Alexion’s Klygefa, and Teva’s Igalm.

Sustainable competitive advantage requires combining proprietary evidence, AI, and human expertise—not substituting one for another.






















